SCHEMBL6981244

SCHEMBL6981244

CCCCS(=O)(=O)Nc1ccc2c(c1)CCCN2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.49
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
AURKA O14965 1/20 0.46
KDR P35968 1/20 0.46
AURKB Q96GD4 1/20 0.46
AR P10275 1/20 0.45
LMNA P02545 3/20 0.45
HPGD P15428 3/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HTT P42858 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11698451 0.80 CA12 (0.54) CA12CA1CA2CA9LMNA
SCHEMBL28156613 0.78 LMNA (0.44) BRD4CA12CA1CA2CA9
SCHEMBL29817718 0.78 LMNA (0.44) BRD4CA12CA1CA2CA9
SCHEMBL6984534 0.78 MLNR (0.53) BRD4CA12CA1CA2CA9
SCHEMBL6985107 0.73 LMNA (0.67) BRD4CA12CA1CA2CA9
SCHEMBL6984820 0.73 HTR6 (0.61) BRD4CA12CA1CA2CA9
SCHEMBL6981247 0.72 PARP14 (0.44) BRD4AURKAKDRAURKBAR
SCHEMBL6421787 0.72 RAB9A (0.52) LMNAHPGDALDH1A1KDM4EHTT
SCHEMBL4433435 0.72 MAPT (0.50) CA12CA1CA2CA9LMNA
SCHEMBL6980011 0.72 BRD4 (0.58) BRD4CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed